MA26868A1 - Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases - Google Patents
Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinasesInfo
- Publication number
- MA26868A1 MA26868A1 MA26736A MA26736A MA26868A1 MA 26868 A1 MA26868 A1 MA 26868A1 MA 26736 A MA26736 A MA 26736A MA 26736 A MA26736 A MA 26736A MA 26868 A1 MA26868 A1 MA 26868A1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- unsubstituted
- pregabalin
- compounds
- useful
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 229960001233 pregabalin Drugs 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 abstract 1
- 238000011914 asymmetric synthesis Methods 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- -1 pregabalin Pyrido [2,3-d] pyrimidine-2,7-diamines Chemical class 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000023516 stroke disease Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
DEPOSANT Société dite : WARNER-LAMBERT COMPANY REVENDICATION DE PRIORITES US 25 Janvier 2000 60/178,261 ?Synthèse asymétrique de prégabaline" L'invention propose un procédé pour la préparation d'acide (S)-(+)-3-(aminomethyl)-5-méthylhexanoïque (prégabaline) ou d'un de ses sels par une synthèse par hydrogénation asymétrique. La prégabaline est utile pour le traitement et la prévention d'attaques cérébrales, de la douleur et de troubles psychotiques. La présente invention propose également des intermédiaires utiles dans la production de la prégabaline. Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases Il est décrit des composés de formule (I): dans laquelle R2, R7, R13, R14 et R15 représentent indépendamment l'hydrogène, ou un groupe alkyle inférieur (non)substitué, alcényle inférieur (non)substitué, alcynyle inférieur (non) substitué ou -(CH2)nR12 (non) substitué ; R5 représente un groupe halogéno, cyano, nitro, -R9, -NR9R10 ou -OR9 ; R6 représente un groupe halogéno, cyano, nitro -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, alcényle inférieur (non)substitué ou alcynyle inférieur (non) substitué;R8 représente un groupe -CO2R13,-COR13, -CONR13R14, CSNR13R14,-C (NR13)NR14R15, -SO3R13, -SO2R13, -SO2NR13R14 -PO3R13R14, -POR13R14, -PO(NR13R14)2 R9 et R10 représentent indépendamment l'hydrogène ou un groupe alkyle inférieur (non)substitué; R11 représente un groupe hétéroaryle ou un groupe hétérocyclique ; R12 représente un groupe cycloalkyle, un groupe hétérocyclique, un groupe aryle ou un groupe hétéroaryle ; et n est égal à 0, 1, 2 ou 3. Ces composés et leurs compositions pharmaceutiques sont utiles pour le traitement de troubles de prolifération cellulaire, tels que le cancer et une resténose. Ces composés sont de puissants inhibiteurs de cdks et de kinases à médiation par des facteurs de croissance.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17826100P | 2000-01-25 | 2000-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26868A1 true MA26868A1 (fr) | 2004-12-20 |
Family
ID=22651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA26736A MA26868A1 (fr) | 2000-01-25 | 2002-07-22 | Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1254137A1 (fr) |
| JP (1) | JP4047010B2 (fr) |
| KR (1) | KR20020065939A (fr) |
| CN (1) | CN1395578A (fr) |
| AP (1) | AP2002002586A0 (fr) |
| AR (1) | AR030044A1 (fr) |
| AU (1) | AU2542501A (fr) |
| BG (1) | BG106850A (fr) |
| BR (1) | BR0107751A (fr) |
| CA (1) | CA2397961C (fr) |
| CO (1) | CO5261549A1 (fr) |
| CR (1) | CR6706A (fr) |
| CZ (1) | CZ20022475A3 (fr) |
| DZ (1) | DZ3266A1 (fr) |
| EA (1) | EA200200643A1 (fr) |
| EE (1) | EE200200405A (fr) |
| GT (1) | GT200100016A (fr) |
| HN (1) | HN2001000013A (fr) |
| HU (1) | HUP0204141A3 (fr) |
| IL (1) | IL150545A0 (fr) |
| IS (1) | IS6443A (fr) |
| MA (1) | MA26868A1 (fr) |
| MX (1) | MXPA02007221A (fr) |
| NO (1) | NO20023527L (fr) |
| OA (1) | OA12161A (fr) |
| PA (1) | PA8510701A1 (fr) |
| PE (1) | PE20011066A1 (fr) |
| PL (1) | PL356802A1 (fr) |
| SK (1) | SK10632002A3 (fr) |
| SV (1) | SV2002000294A (fr) |
| TN (1) | TNSN01014A1 (fr) |
| WO (1) | WO2001055147A1 (fr) |
| YU (1) | YU50402A (fr) |
| ZA (1) | ZA200205879B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| JP4524072B2 (ja) | 2000-10-23 | 2010-08-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規化合物 |
| PE20030008A1 (es) * | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| DE60315826T2 (de) | 2002-04-19 | 2008-05-21 | Smithkline Beecham Corp. | Neue verbindungen |
| JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用 |
| US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| WO2006032452A1 (fr) * | 2004-09-21 | 2006-03-30 | F. Hoffmann-La Roche Ag | 6-(2-alkyl-phényl)-pyrido[2,3-d]pyrimidines utiles comme inhibiteurs de la protéine kinase |
| US20090137550A1 (en) | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
| PE20061351A1 (es) | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
| TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
| KR20080002865A (ko) | 2005-03-25 | 2008-01-04 | 글락소 그룹 리미티드 | 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법 |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| ATE449097T1 (de) * | 2005-07-21 | 2009-12-15 | Hoffmann La Roche | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer |
| JP2009504665A (ja) | 2005-08-09 | 2009-02-05 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| EP1914234A1 (fr) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| FR2910813B1 (fr) * | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | Nouvelle utilisation therapeutique pour le traitement des leucemies |
| EP2112150B1 (fr) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Inhibiteurs Raf améliorés |
| JP5697601B2 (ja) * | 2008-12-01 | 2015-04-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| EP2968331B1 (fr) * | 2013-03-14 | 2020-07-01 | Icahn School of Medicine at Mount Sinai | Composés pyrimidines en tant qu'inhibiteurs de kinase |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR101671404B1 (ko) * | 2014-09-02 | 2016-11-02 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도 |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2146782T3 (es) * | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU763839B2 (en) * | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
-
2001
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 EP EP01900591A patent/EP1254137A1/fr not_active Withdrawn
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/fr not_active Application Discontinuation
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Application Discontinuation
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 CA CA002397961A patent/CA2397961C/fr not_active Expired - Fee Related
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
-
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26868A1 (fr) | Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases | |
| TNSN05250A1 (fr) | Pyrimidinones substituees | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| US7745646B2 (en) | Bicyclic heteroaryl inhibitors of PDE4 | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| JP7450559B2 (ja) | 疾患の処置のためのｋｄｍ１ａ阻害剤 | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA27439A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
| MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
| MA28429B1 (fr) | Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases | |
| BR0201087A (pt) | Compostos antiinflamatórios de benzotriazol | |
| MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
| MA26991A1 (fr) | Triazolopyridines servant d'agents anti-inflammatoires | |
| MA30360B1 (fr) | Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k | |
| MA27440A1 (fr) | Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf) | |
| PL1678166T3 (pl) | Inhibitory kinaz białkowych | |
| MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
| IL176546A0 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
| WO2002078639A2 (fr) | Traitement de maladies proliferatives au moyen d'inhibiteurs de eg5 | |
| MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
| JP2020531574A (ja) | 化合物、その医薬組成物及びその使用及び応用 | |
| CN108699080B (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |